SCHEMBL701030

SCHEMBL701030

COC(=O)c1cccc2c1ccn2Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.53
HTR6 P50406 2/20 0.53
L3MBTL1 Q9Y468 3/20 0.51
GAA P10253 1/20 0.51
CNR1 P21554 1/20 0.51
CNR2 P34972 1/20 0.51
MAPK1 P28482 2/20 0.50
APP P05067 1/20 0.50
TSHR P16473 1/20 0.49
ALDH1A1 P00352 1/20 0.48
HTT P42858 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
ADORA1 P30542 2/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086045 0.90 KMT2A (0.48) NR4A2GAACNR2ALDH1A1HTT
SCHEMBL1079446 0.88 CHRM1 (0.53) NR4A2GAAKMT2ALMNA
SCHEMBL6709394 0.88 POLB (0.55) NR4A2HTR6L3MBTL1GAACNR2
SCHEMBL8387356 0.85 HTR6 (0.57) HTR6L3MBTL1GAACNR1CNR2
SCHEMBL23259262 0.84 LMNA (0.58) HTR6L3MBTL1GAACNR1CNR2
SCHEMBL5422616 0.84 ALDH1A1 (0.49) NR4A2GAAALDH1A1MEN1KMT2A
SCHEMBL2430574 0.83 NR4A2 (0.72) NR4A2L3MBTL1GAACNR1CNR2
SCHEMBL13824516 0.83 NR4A2 (0.67) NR4A2L3MBTL1GAACNR1TSHR
SCHEMBL4348470 0.83 TSHR (0.52) NR4A2L3MBTL1GAACNR1CNR2
SCHEMBL27811762 0.81 NOTUM (0.57) HTR6L3MBTL1GAACNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243160-A1 INDOLE DERIVATIVES FOR TARGETING AUTOPHAGY Automera PTE. LTD (SG) 2025-07-31 US disclosed
US-20220127266-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-04-28 US disclosed
US-11225480-B2 Malic enzyme inhibitors SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-01-18 US disclosed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 US disclosed
US-9988379-B2 GPR40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent LG CHEM, LTD. (KR) 2018-06-05 US disclosed
US-20150291584-A1 GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT LG CHEM, LTD. (KR) 2015-10-15 US disclosed
EP-2917180-A1 GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT LG Life Sciences Ltd. (KR) 2015-09-16 EP disclosed
CN-104837816-A GPR40 receptor agonist, method for preparing same, and pharmaceutical composition containing same as active ingredient LG LIFE SCIENCES LTD 2015-08-12 CN disclosed
WO-2014073904-A1 GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT LG LIFE SCIENCES LTD. (KR) 2014-05-15 WO disclosed
US-8710047-B2 5-HT3 receptor modulators, methods of making, and use thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2014-04-29 US disclosed
CN-102046176-A 5-HT3Receptor modulators, methods of preparation and uses thereof ALBANY MOLECULAR RES INC 2011-05-04 CN disclosed
EP-2310019-A2 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF Albany Molecular Research, Inc. (US) 2011-04-20 EP disclosed
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-07-15 US disclosed
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-07-15 US disclosed
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-07-15 US disclosed
WO-2009155054-A2 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2009-12-23 WO disclosed
WO-2009155054-A2 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2009-12-23 WO disclosed
US-20090298809-A1 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2009-12-03 US disclosed
US-20090298809-A1 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2009-12-03 US disclosed
CN-101282976-A Xanthine derivatives as selective HM74A agonists SMITHKLINE BEECHAM CORP (US) 2008-10-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291584-A1 GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT GPR119, GPR65, GPR55 NR4A2 108/4885HTR6 907/4885L3MBTL1 4875/4885
US-20210115038-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 NR4A2 3495/4885HTR6 4816/4885L3MBTL1 1110/4885
US-11225480-B2 Malic enzyme inhibitors ME1, RNASE1, ME2 NR4A2 3559/4885HTR6 4870/4885L3MBTL1 990/4885
US-20090298809-A1 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF HTR3A, HTR5A, HTR3B NR4A2 3653/4885HTR6 8/4885L3MBTL1 4114/4885
US-20220127266-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 NR4A2 3495/4885HTR6 4816/4885L3MBTL1 1110/4885
US-20250243160-A1 INDOLE DERIVATIVES FOR TARGETING AUTOPHAGY SQSTM1, ATG7, BECN1 NR4A2 3001/4885HTR6 75/4885L3MBTL1 282/4885
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS XDH, GPR84, GPR88 NR4A2 311/4885HTR6 295/4885L3MBTL1 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.